Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Tempest Therapeutics, Inc. Director's Dealing 2014

Jun 25, 2014

34632_dirs_2014-06-25_30c0f73e-7ebb-4a87-8823-6f238b73b089.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: OvaScience, Inc. (OVAS)
CIK: 0001544227
Period of Report: 2014-06-23

Reporting Person: Dipp Michelle (Director, President and CEO, 10% Owner)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2014-06-23 Common Stock P 450 $8.68 Acquired 818093 Direct

Holdings (Non-Derivative)

Security Shares Ownership
Common Stock 3820571 Indirect

Footnotes

F1: The purchase reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan.

F2: Represents 770,016 shares of common stock and 48,077 RSUs.

F3: Longwood Fund GP, LLC is the general partner of Longwood Fund, LP. Voting and investment power with respect to the shares held by Longwood Fund, LP are vested in the Reporting Person, Richard Aldrich, and Christoph Westphal, M.D., Ph.D. (collectively, the "Managers"), the managers of Longwood Fund GP, LLC. Each of the Managers disclaims beneficial ownership of the shares held by Longwood Fund, LP, except to the extent of their respective pecuniary interest therein, and the inclusion of these shares in the report shall not be deemed an admission of beneficial ownership of the shares for purposes of Section 16 or for any other purpose.